Forte Biosciences Amends 8-K Filing on Security Holder Vote

Ticker: FBRX · Form: 8-K/A · Filed: Feb 16, 2024 · CIK: 1419041

Sentiment: neutral

Topics: amendment, corporate-governance, SEC-filing

TL;DR

**Forte Biosciences filed an 8-K/A, updating details on a security holder vote from September 2023.**

AI Summary

Forte Biosciences, Inc. filed an 8-K/A Amendment No. 2 on February 16, 2024, pertaining to an event reported on September 19, 2023. The filing updates information regarding the submission of matters to a vote of security holders. Forte Biosciences, Inc. is incorporated in Delaware with its business address at 3060 Pegasus Park Dr., Building 6, Dallas, Texas 75247.

Why It Matters

This amendment provides updated information on a previous filing, ensuring transparency and accuracy for investors regarding corporate governance matters.

Risk Assessment

Risk Level: low — This is an amendment to a previous filing, providing updated information rather than announcing a new, high-impact event.

Key Players & Entities

FAQ

What is the purpose of this 8-K/A filing by Forte Biosciences, Inc.?

The purpose of this 8-K/A filing (Amendment No. 2) is to update information regarding the submission of matters to a vote of security holders, as initially reported on September 19, 2023.

When was the earliest event reported that this 8-K/A refers to?

The earliest event reported that this 8-K/A refers to was on September 19, 2023.

What is the full business address of Forte Biosciences, Inc. as stated in the filing?

The full business address of Forte Biosciences, Inc. is 3060 Pegasus Park Dr. Building 6, Dallas, Texas 75247.

What is the Commission File Number for Forte Biosciences, Inc.?

The Commission File Number for Forte Biosciences, Inc. is 001-38052.

What is the Registrant's telephone number?

The Registrant's telephone number, including area code, is (310) 618-6994.

Filing Stats: 772 words · 3 min read · ~3 pages · Grade level 13.1 · Accepted 2024-02-16 16:16:05

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FORTE BIOSCIENCES, INC. Date: February 16, 2024 By: /s/ Antony Riley Antony Riley Chief Financial Officer

View Full Filing

View this 8-K/A filing on SEC EDGAR

View on Read The Filing